8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): October 25, 2007

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

Delaware	1-1136	22-079-0350
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On October 25, 2007, Bristol-Myers Squibb Company (the “Company”) filed a Form 8-K furnishing its press release that announced the Company’s financial results for the third quarter of 2007 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was certain supplemental information posted on the Company’s website at www.bms.com. This supplemental information has been revised to include net sales, months on hand, and estimated demand information for key products as of September 30, 2007 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of June 30, 2007, September 30, 2006 and June 30, 2006. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.2. Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRISTOL-MYERS SQUIBB COMPANY
Dated: November 30, 2007	By:	/s/ Sandra Leung
	Name:	Sandra Leung
	Title:	Senior Vice President and General Counsel

EXHIBIT INDEX

Exhibit No.	Description
99.2	Certain supplemental information posted on Bristol-Myers Squibb Company’s website at www.bms.com

EX-99.2

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

NET SALES

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2006																					2007																	% Change
Net Sales	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Pharmaceuticals	$	3,700		$	3,859		$	7,559		$	3,154		$	10,713		$	3,148		$	13,861		$	3,457		$	3,851		$	7,308		$	3,926		$	11,234				24	%	5	%
US Pharmaceuticals		2,064			2,197			4,261			1,609			5,870			1,501			7,371			1,932			2,235			4,167			2,295			6,462				43	%	10	%
Primary Care		1,409			1,441			2,850			819			3,669			648			4,317			1,090			1,344			2,434			1,363			3,797				66	%	3	%
Oncology/Virology		419			458			877			494			1,371			525			1,896			504			511			1,015			539			1,554				9	%	13	%
Neuroscience		231			280			511			262			773			297			1,070			298			327			625			336			961				28	%	24	%
Immunoscience		5			18			23			34			57			31			88			40			53			93			57			150				68	%	163	%
Europe and Middle East Medicines		1,024			1,000			2,024			886			2,910			934			3,844			916			939			1,855			944			2,799				7	%	-4	%
Latin America/Canada		288			303			591			300			891			306			1,197			297			311			608			331			939				10	%	5	%
Asia/Pacific Medicines		279			320			599			318			917			349			1,266			289			333			622			319			941				—		3	%
Health Care Group		976			1,012			1,988			1,000			2,988			1,065			4,053			1,019			1,077			2,096			1,124			3,220				12	%	8	%
Nutritionals		565			582			1,147			582			1,729			618			2,347			606			620			1,226			675			1,901				16	%	10	%
Other Health Care		411			430			841			418			1,259			447			1,706			413			457			870			449			1,319				7	%	5	%
ConvaTec		230			262			492			265			757			291			1,048			254			286			540			292			832				10	%	10	%
Medical Imaging		181			168			349			153			502			156			658			159			171			330			157			487				3	%	-3	%
Total Company	$	4,676		$	4,871		$	9,547		$	4,154		$	13,701		$	4,213		$	17,914		$	4,476		$	4,928		$	9,404		$	5,050		$	14,454				22	%	5	%
	2006																					2007																	Basis Point Change
% of Total Sales	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Pharmaceuticals		79.1	%		79.2	%		79.2	%		75.9	%		78.2	%		74.7	%		77.4	%		77.2	%		78.1	%		77.7	%		77.7	%		77.7	%			180		(50	)
US Pharmaceuticals		44.1	%		45.1	%		44.6	%		38.7	%		42.8	%		35.6	%		41.1	%		43.2	%		45.4	%		44.3	%		45.4	%		44.7	%			670		190
Primary Care		30.1	%		29.6	%		29.9	%		19.7	%		26.8	%		15.4	%		24.1	%		24.4	%		27.3	%		25.9	%		26.9	%		26.3	%			720		(50	)
Oncology/Virology		9.0	%		9.4	%		9.2	%		11.9	%		10.0	%		12.5	%		10.5	%		11.3	%		10.4	%		10.8	%		10.7	%		10.8	%			(120	)	80
Neuroscience		4.9	%		5.7	%		5.3	%		6.3	%		5.6	%		7.0	%		6.0	%		6.7	%		6.6	%		6.6	%		6.7	%		6.6	%			40		100
Immunoscience		0.1	%		0.4	%		0.2	%		0.8	%		0.4	%		0.7	%		0.5	%		0.8	%		1.1	%		1.0	%		1.1	%		1.0	%			30		60
Europe and Middle East Medicines		21.9	%		20.5	%		21.2	%		21.3	%		21.2	%		22.2	%		21.5	%		20.5	%		19.1	%		19.7	%		18.7	%		19.4	%			(260	)	(180	)
Latin America/Canada		6.2	%		6.2	%		6.2	%		7.2	%		6.5	%		7.3	%		6.7	%		6.6	%		6.3	%		6.5	%		6.6	%		6.5	%			(60	)	—
Asia/Pacific Medicines		6.0	%		6.6	%		6.3	%		7.7	%		6.7	%		8.3	%		7.1	%		6.5	%		6.8	%		6.6	%		6.3	%		6.5	%			(140	)	(20	)
Health Care Group		20.9	%		20.8	%		20.8	%		24.1	%		21.8	%		25.3	%		22.6	%		22.8	%		21.9	%		22.3	%		22.3	%		22.3	%			(180	)	50
Nutritionals		12.1	%		12.0	%		12.0	%		14.0	%		12.6	%		14.7	%		13.1	%		13.5	%		12.6	%		13.0	%		13.4	%		13.2	%			(60	)	60
Other Health Care		8.8	%		8.8	%		8.8	%		10.1	%		9.2	%		10.6	%		9.5	%		9.3	%		9.3	%		9.3	%		8.9	%		9.1	%			(120	)	(10	)
ConvaTec		4.9	%		5.4	%		5.2	%		6.4	%		5.5	%		6.9	%		5.8	%		5.7	%		5.8	%		5.8	%		5.8	%		5.7	%			(60	)	20
Medical Imaging		3.9	%		3.4	%		3.6	%		3.7	%		3.7	%		3.7	%		3.7	%		3.6	%		3.5	%		3.5	%		3.1	%		3.4	%			(60	)	(30	)
Total Company		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%

* In Excess of +/- 200%

1

BRISTOL-MYERS SQUIBB COMPANY

SEGMENT SALES AND COMPOSITION OF CHANGE IN SALES FOR TOTAL COMPANY

FOR THE PERIOD ENDED SEPTEMBER 30, 2007

($ in millions)

QUARTER-TO-DATE

	Pharmaceuticals			Nutritionals			ConvaTec			Medical Imaging			Total Company
Price Increases/(Decreases)		4	%		3	%		-1	%		8	%		4	%
Foreign Exchange		3	%		4	%		5	%		1	%		3	%
Volume		17	%		9	%		6	%		-6	%		15	%
Total Change		24	%		16	%		10	%		3	%		22	%
Total 2007 Period to Date Sales	$	3,926		$	675		$	292		$	157		$	5,050
Total 2006 Period to Date Sales	$	3,154		$	582		$	265		$	153		$	4,154
YEAR-TO-DATE
	Pharmaceuticals			Nutritionals			ConvaTec			Medical Imaging			Total Company
Price Increases/(Decreases)		2	%		2	%		-1	%		1	%		1	%
Foreign Exchange		2	%		3	%		5	%		1	%		2	%
Volume		1	%		5	%		6	%		-5	%		2	%
Total Change		5	%		10	%		10	%		-3	%		5	%
Total 2007 Period to Date Sales	$	11,234		$	1,901		$	832		$	487		$	14,454
Total 2006 Period to Date Sales	$	10,713		$	1,729		$	757		$	502		$	13,701

2

BRISTOL-MYERS SQUIBB COMPANY

CONSOLIDATED STATEMENT OF EARNINGS

($ in millions, except per share amounts)

	2006																					2007																	% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Net Sales	$	4,676		$	4,871		$	9,547		$	4,154		$	13,701		$	4,213		$	17,914		$	4,476		$	4,928		$	9,404		$	5,050		$	14,454				22	%	5	%
Cost of products sold		1,476			1,568			3,044			1,465			4,509			1,447			5,956			1,392			1,549			2,941			1,622			4,563				11	%	1	%
Marketing, selling and administrative		1,238			1,181			2,419			1,189			3,608			1,311			4,919			1,158			1,209			2,367			1,214			3,581				2	%	-1	%
Advertising and product promotion		295			352			647			286			933			418			1,351			269			368			637			351			988				23	%	6	%
Research and development		750			740			1,490			756			2,246			821			3,067			807			778			1,585			827			2,412				9	%	7	%
Provision for restructuring, net		1			3			4			2			6			53			59			37			7			44			—			44				-100	%	*
Litigation (income)/expense, net		(21	)		(14	)		(35	)		(9	)		(44	)		346			302			—			14			14			—			14				100	%	132	%
Gain on sale of product assets		(200	)		—			(200	)		—			(200	)		—			(200	)		—			(26	)		(26	)		(247	)		(273	)			—		-37	%
Equity in net income of affiliates		(93	)		(125	)		(218	)		(118	)		(336	)		(138	)		(474	)		(126	)		(128	)		(254	)		(139	)		(393	)			-18	%	-17	%
Other expense/(income), net		37			56			93			(34	)		59			240			299			22			—			22			11			33				132	%	-44	%
Total expenses		3,483			3,761			7,244			3,537			10,781			4,498			15,279			3,559			3,771			7,330			3,639			10,969				3	%	2	%
Earnings/(Loss) Before Minority Interest and Income Taxes		1,193			1,110			2,303			617			2,920			(285	)		2,635			917			1,157			2,074			1,411			3,485				129	%	19	%
Provision/(Benefit) for income taxes		328			256			584			193			777			(167	)		610			86			257			343			342			685				77	%	-12	%
Minority interest, net of taxes		151			187			338			86			424			16			440			141			194			335			211			546				145	%	29	%
Net Earnings/(Loss)	$	714		$	667		$	1,381		$	338		$	1,719		($	134	)	$	1,585		$	690		$	706		$	1,396		$	858		$	2,254				154	%	31	%
Interest expense on conversion of convertible debt bonds, net of tax		8			8			16			9			25			—	(a)		—	(b)		9			9			18			10			28
Net Earnings/(Loss) used for diluted earnings per common share calculation	$	722		$	675		$	1,397		$	347		$	1,744		($	134	)(a)	$	1,585	(b)	$	699		$	715		$	1,414		$	868		$	2,282
Diluted Earnings/(Loss) per Common Share**	$	0.36		$	0.34		$	0.70		$	0.17		$	0.88		($	0.07	)(a)	$	0.81	(b)	$	0.35		$	0.36		$	0.71		$	0.43		$	1.14				153	%	30	%
Average Common Shares Outstanding—Diluted		1,988			1,994			1,992			1,992			1,991			1,961	(a)		1,963	(b)		1,997			2,006			2,002			2,012			2,005				1	%	1	%
Dividends declared per common share	$	0.28		$	0.28		$	0.56		$	0.28		$	0.84		$	0.28		$	1.12		$	0.28		$	0.28		$	0.56		$	0.28		$	0.84				—		—
	2006																					2007																	Basis Point Change
% of Net Sales	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Gross Margin		68.4	%		67.8	%		68.1	%		64.7	%		67.1	%		65.7	%		66.8	%		68.9	%		68.6	%		68.7	%		67.9	%		68.4	%			320		130
Cost of products sold		31.6	%		32.2	%		31.9	%		35.3	%		32.9	%		34.3	%		33.2	%		31.1	%		31.4	%		31.3	%		32.1	%		31.6	%			(320	)	(130	)
Marketing, selling and administrative		26.5	%		24.2	%		25.3	%		28.6	%		26.3	%		31.1	%		27.5	%		25.9	%		24.5	%		25.2	%		24.0	%		24.8	%			(460	)	(150	)
Advertising and product promotion		6.3	%		7.2	%		6.8	%		6.9	%		6.8	%		9.9	%		7.5	%		6.0	%		7.5	%		6.8	%		7.0	%		6.8	%			10		0
Research and development		16.0	%		15.2	%		15.6	%		18.2	%		16.4	%		19.5	%		17.1	%		18.0	%		15.8	%		16.9	%		16.4	%		16.7	%			(180	)	30
Total expenses		74.5	%		77.2	%		75.9	%		85.1	%		78.7	%		106.8	%		85.3	%		79.5	%		76.5	%		77.9	%		72.1	%		75.9	%			(1,300	)	(280	)
Earnings/(Loss) Before Minority Interest and Income Taxes		25.5	%		22.8	%		24.1	%		14.9	%		21.3	%		-6.8	%		14.7	%		20.5	%		23.5	%		22.1	%		27.9	%		24.1	%			1,300		280
Net Earnings/(Loss)		15.3	%		13.7	%		14.5	%		8.1	%		12.5	%		-3.2	%		8.8	%		15.4	%		14.3	%		14.8	%		17.0	%		15.6	%			890		310
Other Ratios
Effective Tax Rate		27.5	%		23.1	%		25.4	%		31.3	%		26.6	%		58.6	%		23.1	%		9.4	%		22.2	%		16.5	%		24.2	%		19.7	%			(710	)	(690	)
	2006																					2007																	% Change
Other (Income)/Expense, net	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Interest expense	$	116		$	124		$	240		$	130		$	370		$	128		$	498		$	109		$	107		$	216		$	109		$	325				-16	%	-12	%
Interest income		(62	)		(65	)		(127	)		(74	)		(201	)		(73	)		(274	)		(53	)		(62	)		(115	)		(69	)		(184	)			7	%	8	%
Foreign exchange transaction (gains)/losses		(12	)		23			11			(11	)		—			6			6			8			(5	)		3			24			27					*	—
Other, net		(5	)		(26	)		(31	)		(79	)		(110	)		179			69			(42	)		(40	)		(82	)		(53	)		(135	)			33	%	-23	%
	$	37		$	56		$	93		$	(34	)	$	59		$	240		$	299		$	22		$	0		$	22		$	11		$	33				132	%	-44	%

* in excess of +/- 200%

** quarterly amounts may not add to the year-to-date totals due to rounding of individual calculations.

(a) as a result of the Q4 2006 net loss, Diluted Average Common Shares Outstanding and Loss per Common Share are equal to Basic Average Common Shares Outstanding and Loss per Common Share.

(b) assumed interest amount and the assumed conversion of convertible debt are not used for Diluted Earnings per Common Share calculation as the impact of convertible debt is anti-dilutive.

3

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE NET SALES BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2006														2007												% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Total Company	$	4,676	$	4,871	$	9,547	$	4,154	$	13,701	$	4,213	$	17,914	$	4,476	$	4,928	$	9,404	$	5,050	$	14,454			22	%	5	%
PHARMACEUTICALS		3,700		3,859		7,559		3,154		10,713		3,148		13,861		3,457		3,851		7,308		3,926		11,234			24	%	5	%
Cardiovascular		1,917		1,907		3,824		1,239		5,063		1,093		6,156		1,475		1,763		3,238		1,793		5,031			45	%	-1	%
Plavix		986		1,145		2,131		630		2,761		496		3,257		938		1,189		2,127		1,254		3,381			99	%	22	%
Pravachol		536		323		859		192		1,051		146		1,197		135		132		267		86		353			-55	%	-66	%
Avapro/ Avalide		233		280		513		277		790		307		1,097		270		297		567		309		876			12	%	11	%
Coumadin		55		55		110		53		163		57		220		46		52		98		50		148			-6	%	-9	%
Virology		468		524		992		532		1,524		580		2,104		590		608		1,198		647		1,845			22	%	21	%
Reyataz		207		236		443		233		676		255		931		263		254		517		273		790			17	%	17	%
Sustiva Franchise***		175		193		368		201		569		222		791		226		233		459		237		696			18	%	22	%
Baraclude		11		14		25		22		47		36		83		45		59		104		72		176			*		*
Oncology		361		401		762		399		1,161		394		1,555		355		360		715		402		1,117			1	%	-4	%
Erbitux		138		172		310		175		485		167		652		160		162		322		185		507			6	%	5	%
Taxol		147		149		296		137		433		130		563		111		95		206		102		308			-26	%	-29	%
Sprycel		—		—		—		11		11		14		25		21		35		56		46		102			*		*
Affective (Psychiatric) Disorders		323		376		699		354		1,053		404		1,457		408		458		866		467		1,333			32	%	27	%
Abilify**		283		324		607		313		920		362		1,282		366		412		778		420		1,198			34	%	30	%
Immunoscience		5		18		23		34		57		32		89		41		55		96		60		156			76	%	174	%
Orencia		5		18		23		34		57		32		89		41		55		96		60		156			76	%	174	%
Other Pharmaceuticals
Efferalgan		68		62		130		62		192		74		266		81		69		150		71		221			15	%	15	%
HEALTH CARE GROUP		976		1,012		1,988		1,000		2,988		1,065		4,053		1,019		1,077		2,096		1,124		3,220			12	%	8	%
NUTRITIONALS		565		582		1,147		582		1,729		618		2,347		606		620		1,226		675		1,901			16	%	10	%
Enfamil		237		253		490		246		736		271		1,007		254		267		521		281		802			14	%	9	%
Enfagrow		67		59		126		69		195		67		262		72		70		142		74		216			7	%	11	%
OTHER HEALTH CARE		411		430		841		418		1,259		447		1,706		413		457		870		449		1,319			7	%	5	%
CONVATEC		230		262		492		265		757		291		1,048		254		286		540		292		832			10	%	10	%
Ostomy		123		141		264		139		403		151		554		130		150		280		147		427			6	%	6	%
Wound Therapeutics		98		107		205		113		318		123		441		107		119		226		126		352			12	%	11	%
MEDICAL IMAGING		181		168		349		153		502		156		658		159		171		330		157		487			3	%	-3	%
Cardiolite		103		105		208		97		305		103		408		99		106		205		99		304			2	%	—

* In excess of +/- 200%

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** Beginning in the third quarter of 2006, Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. Atripla is sold through a joint venture with Gilead Sciences, Inc.

4

BRISTOL-MYERS SQUIBB COMPANY

DOMESTIC* NET SALES BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2006														2007												% Change				% Change in U.S. Total Prescription****
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
Total Company	$	2,638	$	2,806	$	5,444	$	2,170	$	7,614	$	2,115	$	9,729	$	2,505	$	2,830	$	5,335	$	2,920	$	8,255			35	%	8	%
PHARMACEUTICALS		2,076		2,205		4,281		1,619		5,900		1,517		7,417		1,944		2,243		4,187		2,302		6,489			42	%	10	%
Cardiovascular		1,341		1,330		2,671		752		3,423		616		4,039		1,045		1,279		2,324		1,316		3,640			75	%	6	%
Plavix		850		988		1,838		474		2,312		343		2,655		787		1,015		1,802		1,080		2,882			128	%	25	%	86	%	6	%
Pravachol		302		128		430		73		503		50		553		57		47		104		17		121			-77	%	-76	%	-77	%	-82	%
Avapro/Avalide		139		167		306		159		465		182		647		163		170		333		176		509			11	%	9	%	-4	%	-3	%
Coumadin		47		46		93		45		138		48		186		38		43		81		40		121			-11	%	-12	%	-15	%	-16	%
Virology		259		270		529		292		821		327		1,148		319		323		642		328		970			12	%	18	%
Reyataz		119		122		241		129		370		144		514		143		138		281		141		422			9	%	14	%	10	%	13	%
Sustiva Franchise*****		108		115		223		128		351		144		495		144		147		291		151		442			18	%	26	%	19	%	23	%
Baraclude		9		9		18		14		32		18		50		17		20		37		22		59			57	%	84	%	71	%	86	%
Oncology		159		187		346		201		547		195		742		182		187		369		208		577			3	%	5	%
Erbitux		136		172		308		173		481		165		646		158		160		318		183		501			6	%	4	%	N/A		N/A
Taxol		4		4		8		2		10		2		12		4		4		8		1		9			-50	%	-10	%	N/A		N/A
Sprycel		—		—		—		11		11		11		22		10		14		24		17		41			55	%	*	**	N/A		N/A
Affective (Psychiatric) Disorders		237		286		523		266		789		302		1,091		305		333		638		346		984			30	%	25	%
Abilify**		231		267		498		260		758		294		1,052		293		322		615		329		944			27	%	25	%	10	%	12	%
Immunoscience		5		18		23		34		57		31		88		40		53		93		57		150			68	%	163	%
Orencia		5		18		23		34		57		31		88		40		53		93		57		150			68	%	163	%	N/A		N/A
Other Pharmaceuticals
Efferalgan		—		—		—		—		—		—		—		—		—		—		—		—			—		—		N/A		N/A
HEALTH CARE GROUP		478		508		986		482		1,468		527		1,995		488		511		999		529		1,528			10	%	4	%	N/A		N/A
NUTRITIONALS		247		282		529		267		796		295		1,091		274		275		549		304		853			14	%	7	%
Enfamil		155		174		329		169		498		190		688		171		177		348		195		543			15	%	9	%	N/A		N/A
Enfagrow		—		—		—		—		—		—		—		—		—		—		—		—			—		—		N/A		N/A
OTHER HEALTH CARE		231		226		457		215		672		232		904		214		236		450		225		675			5	%	—
CONVATEC		73		85		158		84		242		101		343		78		93		171		94		265			12	%	10	%
Ostomy		34		41		75		39		114		45		159		34		41		75		42		117			8	%	3	%	N/A		N/A
Wound Therapeutics		30		34		64		36		100		43		143		32		36		68		38		106			6	%	6	%	N/A		N/A
MEDICAL IMAGING		158		141		299		131		430		131		561		136		143		279		131		410			—		-5	%
Cardiolite		91		91		182		86		268		90		358		87		92		179		88		267			2	%	—		N/A		N/A

* This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales does not tie to Total Company sales.

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** In excess of +/- 200%

**** The estimated total U.S. prescription change for the retail and mail order channels are calculated based on Next-Generation Prescription Services (NGPS) version 2.0 data on a weighted-average basis. NGPS data is provided by IMS Health, a supplier of market research for the pharmaceutical industry. The weighted-average basis reflects the fact that mail order prescriptions include a greater volume of product supplied compared to retail prescriptions, which on average are 90 days for mail order and 30 days for retail. The calculation is derived by multiplying NGPS mail order prescription data by a factor that approximates three and adding to this the NGPS retail prescriptions.

***** Beginning in the third quarter of 2006, Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. Atripla is sold through a joint venture with Gilead Sciences, Inc. The change in U.S. total prescriptions growth for the Sustiva Franchise includes both branded Sustiva and Atripla prescription units.

5

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL* NET SALES BY PRODUCT

QUARTERLY SALES TREND ANALYSIS

($ in millions)

	2006														2007												% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr	Year	Qtr vs. Qtr		YTD vs. YTD
Total Company	$	2,038	$	2,065	$	4,103	$	1,984	$	6,087	$	2,098	$	8,185	$	1,971	$	2,098	$	4,069	$	2,130	$	6,199			7	%	2	%
PHARMACEUTICALS		1,624		1,654		3,278		1,535		4,813		1,631		6,444		1,513		1,608		3,121		1,624		4,745			6	%	-1	%
Cardiovascular		576		577		1,153		487		1,640		477		2,117		430		484		914		477		1,391			-2	%	-15	%
Plavix		136		157		293		156		449		153		602		151		174		325		174		499			12	%	11	%
Pravachol		234		195		429		119		548		96		644		78		85		163		69		232			-42	%	-58	%
Avapro/Avalide		94		113		207		118		325		125		450		107		127		234		133		367			13	%	13	%
Coumadin		8		9		17		8		25		9		34		8		9		17		10		27			25	%	8	%
Virology		209		254		463		240		703		253		956		271		285		556		319		875			33	%	24	%
Reyataz		88		114		202		104		306		111		417		120		116		236		132		368			27	%	20	%
Sustiva Franchise****		67		78		145		73		218		78		296		82		86		168		86		254			18	%	17	%
Baraclude		2		5		7		8		15		18		33		28		39		67		50		117			*		*
Oncology		202		214		416		198		614		199		813		173		173		346		194		540			-2	%	-12	%
Erbitux		2		—		2		2		4		2		6		2		2		4		2		6			—		50	%
Taxol		143		145		288		135		423		128		551		107		91		198		101		299			-25	%	-29	%
Sprycel		—		—		—		—		—		3		3		11		21		32		29		61			—		—
Affective (Psychiatric) Disorders		86		90		176		88		264		102		366		103		125		228		121		349			38	%	32	%
Abilify**		52		57		109		53		162		68		230		73		90		163		91		254			72	%	57	%
Immunoscience		—		—		—		—		—		1		1		1		2		3		3		6			—		—
Orencia		—		—		—		—		—		1		1		1		2		3		3		6			—		—
Other Pharmaceuticals
Efferalgan		68		62		130		62		192		74		266		81		69		150		71		221			15	%	15	%
HEALTH CARE GROUP		498		504		1,002		518		1,520		538		2,058		531		566		1,097		595		1,692			15	%	11	%
NUTRITIONALS		318		300		618		315		933		323		1,256		332		345		677		371		1,048			18	%	12	%
Enfamil		82		79		161		77		238		81		319		83		90		173		86		259			12	%	9	%
Enfagrow		67		59		126		69		195		67		262		72		70		142		74		216			7	%	11	%
OTHER HEALTH CARE		180		204		384		203		587		215		802		199		221		420		224		644			10	%	10	%
CONVATEC		157		177		334		181		515		190		705		176		193		369		198		567			9	%	10	%
Ostomy		89		100		189		100		289		106		395		96		109		205		105		310			5	%	7	%
Wound Therapeutics		68		73		141		77		218		80		298		75		83		158		88		246			14	%	13	%
MEDICAL IMAGING		23		27		50		22		72		25		97		23		28		51		26		77			18	%	7	%
Cardiolite		12		14		26		11		37		13		50		12		14		26		11		37			—		—

* This table presents Total Company sales on a legal entity source basis and segment and product sales on a country management reported basis. As a result, the sum of segment sales does not tie to Total Company sales.

** Includes alliance revenue from the co-promotional agreement with Otsuka Pharmaceutical Co., Ltd.

*** In excess of +/- 200%

**** Beginning in the third quarter of 2006, Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. Atripla is sold through a joint venture with Gilead Sciences, Inc.

6

BRISTOL-MYERS SQUIBB COMPANY

U.S. PHARMACEUTICALS AND PLAVIX NET SALES

EXCLUDING ESTIMATED IMPACT OF LAUNCH OF GENERIC CLOPIDOGREL BISULFATE

($ in millions)

	2007 Q3		2006 Q3		% Change Qtr vs. Qtr
U.S Pharmaceuticals Net Sales
U.S Pharmaceuticals Net Sales as Reported	$	2,295		$1,609	43	%
Estimated Impact of Launch of Generic Clopidogrel Bisulfate		—		525 to 600	—
U.S Pharmaceuticals Net Sales Excluding the Estimated Impact of Launch of Generic Clopidogrel Bisulfate	$	2,295	$	2,134 to $2,209	4% to 8	%
	2007 Q3		2006 Q3		% Change Qtr vs. Qtr
U.S Plavix Net Sales
U.S Plavix Net Sales as Reported	$	1,080		$474	128	%
Estimated Impact of Launch of Generic Clopidogrel Bisulfate		—		525 to 600	—
U.S Plavix Net Sales Excluding the Estimated Impact of Launch of Generic Clopidogrel Bisulfate	$	1,080	$	999 to $1,074	1% to 8	%

7

BRISTOL-MYERS SQUIBB COMPANY

GROSS MARGIN

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2007
	Q1			Q2			Q3						TOTAL YEAR
Net Sales	$	4,476		$	4,928		$	5,050					$	14,454
Gross Profit
Gross Profit	$	3,084		$	3,379		$	3,428					$	9,891
Specified items*		16			13			17						46
Gross Profit Excluding Specified Items	$	3,100		$	3,392		$	3,445					$	9,937
Gross Margin %
Gross Margin %		68.9	%		68.6	%		67.9	%					68.4	%
Specified items*		0.4	%		0.2	%		0.3	%					0.3	%
Gross Margin % Excluding Specified Items		69.3	%		68.8	%		68.2	%					68.7	%
	2006
	Q1			Q2			Q3			Q4			TOTAL YEAR
Net Sales	$	4,676		$	4,871		$	4,154		$	4,213		$	17,914
Gross Profit
Gross Profit	$	3,200		$	3,303		$	2,689		$	2,766		$	11,958
Specified items*		46			20			72			29			167
Gross Profit Excluding Specified Items	$	3,246		$	3,323		$	2,761		$	2,795		$	12,125
Gross Margin %
Gross Margin %		68.4	%		67.8	%		64.7	%		65.7	%		66.8	%
Specified items*		1.0	%		0.4	%		1.8	%		0.6	%		0.9	%
Gross Margin % Excluding Specified Items		69.4	%		68.2	%		66.5	%		66.3	%		67.7	%

* Please refer to the Specified Item - QTD tab for detail of specified items.

8

BRISTOL-MYERS SQUIBB COMPANY

RESEARCH AND DEVELOPMENT EXPENSES

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2007
	Q1		Q2		Q3				TOTAL YEAR
Research and Development Expenses	$	807	$	778	$	827			$	2,412
Specified items*		80		17		60				157
Research and Development Expenses Excluding Specified Items	$	727	$	761	$	767			$	2,255
	2006
	Q1		Q2		Q3		Q4		TOTAL YEAR
Research and Development Expenses	$	750	$	740	$	756	$	821	$	3,067
Specified items*		18		1		17		49		85
Research and Development Expenses Excluding Specified Items	$	732	$	739	$	739	$	772	$	2,982

* Please refer to the Specified Item—QTD tab for detail of specified items.

9

BRISTOL-MYERS SQUIBB COMPANY

EFFECTIVE TAX RATE

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2007
	Q1			Q2			Q3						TOTAL YEAR
Provision for Income Taxes
Provision for Income Taxes	$	86		$	257		$	342					$	685
Specified items*		79			5			(82	)					2
Provision for Income Taxes Excluding Specified Items	$	165		$	262		$	260					$	687
Earnings Before Minority Interest and Provision for Income Taxes	$	917		$	1,157		$	1,411					$	3,485
Earnings Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,050		$	1,182		$	1,235					$	3,467
Effective Tax Rate
Effective Tax Rate		9.4	%		22.2	%		24.2	%					19.7	%
Effective Tax Rate Excluding Specified Items		15.7	%		22.2	%		21.1	%					19.8	%
	2006
	Q1			Q2			Q3			Q4			TOTAL YEAR
Provision for Income Taxes
Provision/(Benefit) for Income Taxes	$	328		$	256		$	193		$	(167	)	$	610
Specified items*		(49	)		(3	)		(34	)		196			110
Provision for Income Taxes Excluding Specified Items	$	279		$	253		$	159		$	29		$	720
Earnings/(Loss) Before Minority Interest and Provision for Income Taxes	$	1,193		$	1,110		$	617		$	(285	)	$	2,635
Earnings Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,081		$	1,120		$	670		$	425		$	3,296
Effective Tax Rate
Effective Tax Rate		27.5	%		23.1	%		31.3	%		58.6	%		23.1	%
Effective Tax Rate Excluding Specified Items		25.8	%		22.6	%		23.7	%		6.8	%		21.8	%

* Please refer to the Specified Item—QTD tab for detail of specified items.

10

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS BEFORE MINORITY INTEREST AND INCOME TAXES

EXCLUDING SPECIFIED ITEMS

($ in millions)

	2007
	Q1			Q2			Q3						TOTAL YEAR
Earnings Before Minority Interest and Provision for Income Taxes	$	917		$	1,157		$	1,411					$	3,485
Specified items:
Upfront and milestone payments		80			17			60						157
Downsizing and streamlining of worldwide operations		53			20			17						90
Litigation matters		—			14			5						19
Insurance recoveries		—			—			(11	)					(11	)
Gain on sale of product assets		—			(26	)		(247	)					(273	)
Subtotal		133			25			(176	)					(18	)
Earnings Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,050		$	1,182		$	1,235					$	3,467
	2006
	Q1			Q2			Q3			Q4			TOTAL YEAR
Earnings / (Loss) Before Minority Interest and Provision for Income Taxes	$	1,193		$	1,110		$	617		($	285	)	$	2,635
Specified items:
Gain on sale of product asset		(200	)		—			—			—			(200	)
Litigation matters		40			(14	)		(29	)		353			350
Insurance recoveries		(21	)		—			(9	)		(7	)		(37	)
Downsizing and streamlining of worldwide operations		69			24			91			131			315
Debt retirement costs		—			—			—			220			220
Claim for damages		—			—			—			13			13
Subtotal		(112	)		10			53			710			661
Earnings Before Minority Interest and Provision for Income Taxes Excluding Specified Items	$	1,081		$	1,120		$	670		$	425		$	3,296

11

BRISTOL-MYERS SQUIBB COMPANY

DILUTED EARNINGS PER COMMON SHARE

EXCLUDING SPECIFIED ITEMS

	2007
	Q1			Q2			Q3						TOTAL YEAR *
Diluted Earnings per Common Share	$	0.35		$	0.36		$	0.43					$	1.14
Specified items:
Upfront and milestone payments		0.03			0.01			0.01						0.05
Downsizing and streamlining of worldwide operations		0.02			0.01			0.01						0.04
Gain on sale of product assets		—			(0.01	)		(0.07	)					(0.08	)
Tax item		(0.02	)		—			—						(0.02	)
Subtotal		0.03			0.01			(0.05	)					(0.01	)
Diluted Earnings per Common Share Excluding Specified Items	$	0.38		$	0.37		$	0.38					$	1.13
	2006
	Q1			Q2			Q3			Q4			TOTAL YEAR *
Diluted Earnings / (Loss) per Common Share	$	0.36		$	0.34		$	0.17		$	(0.07	)	$	0.81
Specified items:
Gain on sale of product asset		(0.06	)		—			—			—			(0.06	)
Litigation matters		0.01			—			(0.01	)		0.14			0.14
Insurance recoveries		(0.01	)		—			—			—			(0.01	)
Downsizing and streamlining of worldwide operations / other		0.02			0.01			0.04			0.05			0.12
Debt retirement costs		—			—			—			0.07			0.07
Tax item		—			—			0.02			—			0.02
Subtotal		(0.04	)		0.01			0.05			0.26			0.28
Diluted Earnings per Common Share Excluding Specified Items	$	0.32		$	0.35		$	0.22		$	0.19		$	1.09

* quarterly amounts may not add to the annual total due to rounding of individual calculations.

12

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

($ in millions)

Three months ended September 30, 2007

	Cost of products sold		Research and development		Gain on sale of product assets			Other (income)/expense, net			Total
Litigation Matters:
Insurance recovery	$	—	$	—	$	—		$	(11	)	$	(11	)
Product liability		—		—		—			5			5
		—		—		—			(6	)		(6	)
Other:
Upfront and milestone payments		—		60		—			—			60
Accelerated depreciation and asset impairment		17		—		—			—			17
Gain on sale of product assets		—		—		(247	)		—			(247	)
	$	17	$	60	$	(247	)	$	(6	)		(176	)
Income taxes on items above												82
(Increase)/Decrease to Net Earnings											$	(94	)

Three months ended September 30, 2006

	Cost of products sold		Research and development		Provision for restructuring, net		Litigation income, net			Other (income)/ expense, net			Total
Litigation Matters:
Insurance recovery	$	—	$	—	$	—	$	(9	)	$	—		$	(9	)
Product liability		—		—		—		—			11			11
Commercial litigation		—		—		—		—			(40	)		(40	)
		—		—		—		(9	)		(29	)		(38	)
Other:
Accelerated depreciation and asset impairment		72		—		—		—			—			72
Downsizing and streamlining of worldwide operations		—		—		2		—			—			2
Upfront and milestone payments		—		17		—		—			—			17
	$	72	$	17	$	2	$	(9	)	$	(29	)		53
Income taxes on items above														(5	)
Minority interest, net of taxes														13
Change in estimate for taxes on prior year items														39
(Increase)/Decrease to Net Earnings													$	100

13

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

($ in millions)

Nine months ended September 30, 2007

	Cost of products sold		Research and development		Provision for restructuring, net		Litigation expense, net		Other (income)/ expense, net			Gain on sale of product assets			Total
Litigation Matters:
Litigation settlement	$	—	$	—	$	—	$	14	$	—		$	—		$	14
Insurance recovery		—		—		—		—		(11	)		—			(11	)
Product liability		—		—		—		—		5			—			5
		—		—		—		14		(6	)		—			8
Other:
Upfront and milestone payments		—		157		—		—		—			—			157
Accelerated depreciation and asset impairment		46		—		—		—		—			—			46
Downsizing and streamlining of worldwide operations		—		—		44		—		—			—			44
Gain on sale of product assets		—		—		—		—		—			(273	)		(273	)
	$	46	$	157	$	44	$	14	$	(6	)	$	(273	)		(18	)
Income taxes on items above																37
Change in estimate for taxes on a prior year specified item																(39	)
(Increase)/Decrease to Net Earnings															$	(20	)

Nine months ended September 30, 2006

	Cost of products sold		Research and development		Marketing selling and administrative		Provision for restructuring, net		Litigation income, net			Other (income)/ expense, net		Gain on sale of product asset			Total
Litigation Matters:
Insurance recovery	$	—	$	—	$	—	$	—	$	(30	)	$	—	$	—		$	(30	)
Product liability		—		—		—		—		—			11		—			11
Commercial litigations		—		—		—		—		(14	)		—		—			(14	)
		—		—		—		—		(44	)		11		—			(33	)
Other:
Accelerated depreciation, asset impairment and contract termination		138		1		4		—		—			—		—			143
Downsizing and streamlining of worldwide operations		—		—		—		6		—			—		—			6
Upfront and milestone payments		—		35		—		—		—			—		—			35
Gain on sale of product asset		—		—		—		—		—			—		(200	)		(200	)
	$	138	$	36	$	4	$	6	$	(44	)	$	11	$	(200	)		(49	)
Income taxes on items above																		47
Change in estimate for taxes on prior year items																		39
(Increase)/Decrease to Net Earnings																	$	37

14

BRISTOL-MYERS SQUIBB COMPANY

SELECT BALANCE SHEET INFORMATION

($ in millions)

	March 31,		June 30,		September 30,		December 31,			March 31,		June 30,		September 30,		December 31,
	2006		2006		2006		2006			2007		2007		2007		2007
Cash, cash equivalents and marketable debt securities	$	5,281	$	5,357	$	5,505	$	4,013		$	4,012	$	4,646	$	3,582
Short-term borrowings		234		189		630		187			241		256		1,879
Long-term debt		8,278		8,239		7,837		7,248			7,132		6,978		4,248
Net debt	$	3,231	$	3,071	$	2,962	$	3,422		$	3,361	$	2,588	$	2,545
Receivables, net of allowances	$	3,236	$	3,326	$	2,945	$	3,247		$	3,381	$	3,632	$	3,704
Stockholders' equity		11,556		11,712		11,589		9,991	(1)		10,261		10,762		11,153
Capital expenditures and capitalized software (for the quarter ended)		202		160		199		224			202		206		185

(1) Includes the impact of the adoption of SFAS 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans - an amendment of FASB Statements No. 87, 88, 106 and 132(R)"

15

BRISTOL-MYERS SQUIBB COMPANY

2007 FULL YEAR PROJECTED DILUTED EPS

EXCLUDING PROJECTED SPECIFIED ITEMS

	Full Year 2007
Projected Diluted Earnings per Common Share	$	1.28 to $1.33
Projected Specified Items:
In-process R&D charge		0.12
Upfront and milestone payments		0.06
Downsizing and streamlining of worldwide operations		0.06
Gain on sale of product assets		(0.08	)
Tax item		(0.02	)
Total		0.14
Projected Diluted Earnings per Common Share Excluding Specified Items	$	1.42 to $1.47

2007 and 2008 Gross Margin/Research and Development/Tax Rate Projections Excluding Specified Items

Gross margin on a GAAP basis for the nine months ended September 30, 2007 was 68.4%, which included specified items of $46 million and had a 0.3% adverse impact on gross margin in aggregate. On a non-GAAP basis, for the nine months ended September 30, 2007 gross margin was 68.7%. On a non-GAAP basis, based on historical trends in 2006 and for the nine months ended September 30, 2007 the Company projects gross margin for the full year 2007 to be at least 100 basis points higher than 2006 and for the full year 2008 to improve slightly compared to the full year 2007 estimate. There is no reasonably accessible or reliable comparable GAAP measure for this forward-looking information on gross margin. See Gross Margin non comparable tab.

Research and development expenses on a GAAP basis for the nine months ended September 30, 2007 were $2,412 million, which included specified items of $157 million. On a non-GAAP basis, for the nine months ended September 30, 2007 research and development expenses were $2,255 million. On a non-GAAP basis, based on historical trends in 2006 and for the nine months ended September 30, 2007 the Company projects research and development expenses for the full year 2007 to increase in the mid single digit range compared to 2006 and for the full year 2008 to increase in the mid single digit range compared to the full year 2007 estimate. There is no reasonably accessible or reliable comparable GAAP measure for this forward-looking information on research and development. See R&D non comparable tab.

The effective tax rate on a GAAP basis for the nine months ended September 30, 2007 was 19.7%, which included specified items of $2 million in the tax provision, and had a 0.1% favorable impact on the effective tax rate in aggregate. On a non-GAAP basis, for the nine months ended September 30, 2007 effective tax rate was 19.8%. On a non-GAAP basis, based on historical trends in 2006 and for the nine months ended September 30, 2007 the Company projects effective tax rate for the full year 2007 to be in the 20% range and for the full year 2008 to be in the 22% to 24% range. There is no reasonably accessible or reliable comparable GAAP measure for this forward-looking information on the tax rate. See Tax Rate non comparable tab.

The GAAP results for the full year 2007 and 2008 would include specified items that may occur and impact results, including restructuring and other charges that cannot be reasonably estimated at this time in connection with the Company's comprehensive cost reduction programs, including charges relating to workforce reductions and the rationalization of some facilities. While the amount and timing of these restructuring and other charges cannot be reasonably estimated at this time, the Company expects that the charges are likely to be incurred over the next three years and are reasonably likely to be material. These specified items could also include charges and recoveries relating to significant legal proceedings, debt retirement costs and other charges related to new transactions, upfront and milestone payments, copromotion or alliance charges and charges for in-process research and development related to new external development transactions, gains or losses from asset disposals, restructuring activities and significant tax events. For a fuller discussion of certain of the litigation and other matters that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Company Reports Financial Results For The Third Quarter of 2007, October 25, 2007, including “Outlook for 2007 and 2008” and “Use of Non-GAAP Financial Information” therein.

16

BRISTOL-MYERS SQUIBB COMPANY

ESTIMATED MONTHS ON HAND OF TOP 15 U.S. PHARMACEUTICAL PRODUCTS

IN THE U.S. WHOLESALER DISTRIBUTION CHANNEL

The following tables sets forth, for each of the Company’s top 15 pharmaceutical products (based on 2006 annual net sales) sold by the Company's U.S. Pharmaceuticals business, the U.S. Pharmaceuticals net sales and the estimated number of months on hand of the applicable product in the U.S. wholesaler distribution channel for the quarters ended September 30, 2007 and 2006 and June 30, 2007 and 2006.

	September 30, 2007				September 30, 2006			June 30, 2007			June 30, 2006
	Net Sales			Months on Hand	Net Sales		Months on Hand	Net Sales		Months on Hand	Net Sales		Months on Hand
	(Dollars in Millions)				(Dollars in Millions)			(Dollars in Millions)			(Dollars in Millions)
Abilify (total revenue)	$	329		0.4	$	260	0.5	$	322	0.4	$	267	0.5
Avapro/Avalide		176		0.4		159	0.4		170	0.4		167	0.5
Baraclude		22		0.5		14	0.6		20	0.7		9	0.7
Coumadin		40		0.6		45	0.7		43	0.7		46	0.8
Erbitux (a)		183		0.3		173	0.5		160	0.4		172	—
Glucophage Franchise		17		0.6		20	0.7		17	0.6		22	0.6
Kenalog		20		0.6		19	0.8		26	0.5		22	0.8
Orencia (b)		57		0.4		34	0.8		53	0.5		18	0.3
Paraplatin		(1	)	25.0		5	1.5		1	17.5		2	1.7
Plavix		1,080		0.4		474	1.5		1,015	0.4		988	0.5
Pravachol		17		0.7		73	1.0		47	0.5		128	1.0
Reyataz		141		0.5		129	0.5		138	0.6		122	0.6
Sprycel		17		0.7		11	1.2		14	0.8		—	—
Sustiva Franchise (c) (total revenue)		151		0.6		128	0.5		147	0.7		115	0.5
Zerit		13		0.7		19	0.7		15	0.7		18	0.7

For all products other than Erbitux and Orencia, the Company determines the above months on hand estimates by dividing the estimated amount of the product in the U.S. wholesaler distribution channel by the estimated amount of out-movement of the product from the U.S. wholesaler distribution channel over a period of 31 days, all calculated as described below. Factors that may influence the Company's estimates include generic competition, seasonality of products, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, such estimates are calculated using third-party data, which represent their own record-keeping processes and as such, may also reflect estimates.

Estimates of product in the wholesaler distribution channel and out-movement are based on weekly information received directly from third-parties, and excludes any inventory held by intermediaries such as retailers and hospitals, and excludes goods in transit to such wholesalers. The Company determines the amount of out-movement of a product over a period of 31 days by using the most recent out-movement of a product as provided by these third parties, adjusted to reflect the Company's estimate of goods in transit to these wholesalers. The Company estimates the amount of goods in transit by using information provided by these wholesalers with respect to their open orders and the Company's records of sales to these wholesalers with respect to such open orders.

(a) The Company sells Erbitux to intermediaries (such as wholesalers and specialty oncology distributors) and ships Erbitux directly to the end-users of the product who are the customers of those intermediaries. The Company also sells Erbitux to other distributors who then hold Erbitux inventory. The above estimate of months on hand was calculated by dividing the inventories of Erbitux held by the distributors for their own accounts as reported by the distributors as of the end of the quarter by the out-movements of the product reported by the distributors over the last 31 day period. The inventory levels reported by the distributors are a product of their record-keeping process.

(b) The Company distributes Orencia through distribution arrangements with multiple distributors. The above estimates of months on hand was calculated by dividing the inventories of Orencia held by these distributors at the end of the quarter by the out-movement of the product over the last 31 day period, as reported by these distributors. The inventory on hand and out-movements reported by these distributors are a product of the distributors’ own record-keeping processes.

(c) Beginning in the third quarter of 2006, Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. The estimated months on hand of the product in the U.S. wholesale distribution channel only include branded Sustiva inventory.

17

BRISTOL-MYERS SQUIBB COMPANY

ESTIMATED MONTHS ON HAND OF TOP INTERNATIONAL PHARMACEUTICAL

AND WORLDWIDE NON-PHARMACEUTICAL PRODUCTS

The following table, which was posted on the Company's website and filed on Form 8-K on August 31, 2007, sets forth for each of the Company’s key products sold by the businesses listed below, the net sales of the applicable product for each of the quarters ended June 30, 2007, March 31, 2007, June 30, 2006 and March 31, 2006, and the estimated number of months on hand of the applicable product in the direct customer distribution channel for the business as of the end of each of the four quarters. The estimates of months on hand for key products described below for the International Pharmaceuticals business are based on data collected for all of the Company’s significant business units outside of the U.S. For the other non-Pharmaceuticals reporting segments, estimates are based on data collected for the U.S. and all significant business units outside of the U.S.

	June 30, 2007			March 31, 2007			June 30, 2006			March 31, 2006
	Net Sales		Months on Hand	Net Sales		Months on Hand	Net Sales		Months on Hand	Net Sales		Months on Hand
	(Dollars in Millions)			(Dollars in Millions)			(Dollars in Millions)			(Dollars in Millions)
International Pharmaceuticals
Abilify (total revenue)	$	90	0.6	$	73	0.6	$	57	0.6	$	52	0.6
Avapro/Avalide		127	0.5		107	0.5		113	0.5		94	0.5
Baraclude		39	0.7		28	0.7		5	1.0		2	1.1
Bufferin		27	0.5		24	0.5		31	0.5		22	0.6
Capoten		25	0.9		26	0.8		31	0.9		35	0.8
Dafalgan		42	1.4		44	1.2		37	1.1		37	1.4
Efferalgan		69	1.4		81	1.1		62	0.9		68	1.2
Maxipime		39	0.8		29	0.5		43	0.8		40	0.8
Monopril		42	1.2		36	0.8		48	1.1		46	1.1
Orencia		2	0.4		1	0.3		—	—		—	—
Perfalgan		65	0.5		58	0.5		51	0.6		46	0.6
Plavix		174	0.6		151	0.5		157	0.5		136	0.5
Pravachol		85	0.6		78	0.6		195	1.4		234	1.5
Reyataz		116	0.7		120	0.9		114	0.7		88	0.6
Sprycel		21	0.4		11	0.4		—	—		—	—
Sustiva Franchise (a)		86	0.5		82	0.5		78	0.5		67	0.5
Taxol		91	0.6		107	0.7		145	0.5		143	0.6
Videx/Videx EC		27	1.1		27	1.1		35	1.2		31	0.8
Nutritionals
Enfamil/Enfagrow		337	0.9		326	0.8		312	0.9		304	0.9
Nutramigen		54	1.0		52	0.9		54	1.0		48	1.0
Other Health Care
ConvaTec
Ostomy		150	0.9		130	0.9		141	1.0		123	0.9
Wound Therapeutics		119	0.9		107	0.9		107	0.9		98	0.9
Medical Imaging
Cardiolite		106	0.7		99	0.7		105	0.8		103	0.8

(a) Beginning in the third quarter of 2006, Sustiva Franchise includes sales of Sustiva, as well as revenue of bulk efavirenz included in the combination therapy, Atripla. The estimated months on hand of the product in the distribution channel only include branded Sustiva inventory.

The above months on hand information represents the Company’s estimates of aggregate product level inventory on hand at direct customers divided by the expected demand for the applicable product. Expected demand is the estimated ultimate patient/consumer demand calculated based on estimated end-user consumption or direct customer out-movement data over the most recent 31 day period or other reasonable period. Factors that may affect the Company’s estimates include generic competition, seasonality of products, direct customer purchases in light of price increases, new product or product presentation launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations.

18

Estimated End-User Demand

U.S. Pharmaceuticals

The following tables set forth for each of the Company’s top 15 pharmaceutical products (based on 2006 annual net sales) sold by the U.S. Pharmaceuticals business, for the three months ended September 30, 2007 compared to the same periods in the prior year: (i) changes in reported U.S. net sales for the period; (ii) estimated total U.S. prescription change for the retail and mail order channels calculated by the Company based on NGPS version 2.0 data on a weighted average basis; and (iii) the estimated U.S. therapeutic category share of the applicable product calculated by the Company based on NGPS version 2.0 data on a weighted-average basis. Prior year prescription data has been adjusted to conform to the NGPS version 2.0 data.

	Three Months Ended September 30, 2007				Month Ended September 30, 2007
	Change in U.S. Net Sales(a)		Change in U.S. Total Prescriptions(b)		Estimated TRx Therapeutic Category Share (b, c)
ABILIFY* (total revenue)	27	%	10	%	13	%
AVAPRO*/AVALIDE*	11		(4	)	13
BARACLUDE	57		71		29
COUMADIN	(11	)	(15	)	14
ERBITUX* (d)	6		N/A		N/A
GLUCOPHAGE* Franchise	(15	)	(30	)	1
KENALOG (e)	5		N/A		N/A
ORENCIA(d)	68		N/A		N/A
PARAPLATIN (d)	(120	)	N/A		N/A
PLAVIX*	128		86		87
PRAVACHOL	(77	)	(77	)	—
REYATAZ (f)	9		10		19
SPRYCEL (g)	55		*	*	6
SUSTIVA Franchise (f, h) (total revenue)	18		19		36
ZERIT	(32	)	(29	)	4

	Three Months Ended September 30, 2006				Month Ended September 30, 2006
	Change in U.S. Net Sales(a)		Change in U.S. Total Prescriptions(b)		Estimated TRx Therapeutic Category Share(b, c)
ABILIFY* (total revenue)	21	%	18	%	12	%
AVAPRO*/AVALIDE*	8		1		14
BARACLUDE	*	*	*	*	21
COUMADIN	(8	)	(18	)	16
ERBITUX* (d)	63		N/A		N/A
GLUCOPHAGE* Franchise	(47	)	(52	)	1
KENALOG (e)	—		N/A		N/A
ORENCIA (d)	—		N/A		N/A
PARAPLATIN (d)	(44	)	N/A		N/A
PLAVIX*	(43	)	(36	)	19
PRAVACHOL	(75	)	(82	)	1
REYATAZ (f)	23		14		18
SPRYCEL (g)	—		—		3
SUSTIVA (f)	27		11		32
ZERIT	(21	)	(32	)	5

(a) Reflects percentage change in net sales in dollar terms, including change in average selling prices and wholesaler buying patterns.

19

(b) Derived by multiplying NGPS mail order prescription data by a factor that approximates three and adding to this the NGPS retail prescriptions.

(c) The therapeutic categories are determined by the Company as those products considered to be in direct competition with the Company’s own products. The products listed above compete in the following therapeutic categories: ABILIFY* (antipsychotics), AVAPRO*/AVALIDE* (angiotensin receptor blockers), BARACLUDE (oral antiviral agent), COUMADIN (warfarin), ERBITUX* (oncology), GLUCOPHAGE* Franchise (oral antidiabetics), KENALOG (intra-articular/intramuscular steroid), ORENCIA (fusion protein), PARAPLATIN (carboplatin), PLAVIX* (antiplatelet agents), PRAVACHOL (HMG CoA reductase inhibitors), REYATAZ and the SUSTIVA Franchise (antiretrovirals - third agents excluding NORVIR* and TRIZIVIR*), SPRYCEL (TKIs for leukemia), and ZERIT (nucleoside reverse transcriptase inhibitors).

(d) ERBITUX*, ORENCIA and PARAPLATIN are parenterally administered products and do not have prescription-level data as physicians do not write prescriptions for these products. The Company believes therapeutic category share information provided by third parties for these products may not be reliable and accordingly, none is presented here.

(e) The Company does not have prescription level data because the product is not dispensed through a retail pharmacy. The Company believes therapeutic category share information provided by third parties for this product may not be reliable and accordingly, none is presented here.

(f) REYATAZ and the SUSTIVA Franchise have been recalculated as a percentage share of antiretrovirals – third agents excluding NORVIR* and TRIZIVIR*.

(g) SPRYCEL was launched in the U.S. in July 2006.

(h) SUSTIVA Franchise (total revenue) includes sales of SUSTIVA, as well as revenue of bulk efavirenz included in the combination therapy, ATRIPLA*. The therapeutic category share information and change in U.S. total prescriptions growth for SUSTIVA Franchise (antiretrovirals – third agents excluding NORVIR* and TRIZIVIR*) includes both branded SUSTIVA and ATRIPLA* prescription units.

** In excess of 200%.

The Company is reporting REYATAZ’s estimated TRx category share within the antiretrovirals—third agents (excluding NORVIR* and TRIZIVIR*) category rather than the protease inhibitors (excluding NORVIR*) category. The Company believes that the antiretrovirals - third agents (excluding NORVIR* and TRIZIVIR*) category more closely reflects the use of protease inhibitors, which has evolved and competes with other products within the antiretrovirals—third agents (excluding NORVIR* and TRIZIVIR*) category. The historical trends of growth in REYATAZ’s estimated TRx category share between the two categories are not materially different.

As previously reported, in July 2007, IMS issued a Product News bulletin announcing that it had revised its previously issued projected prescription and unit volumes for PLAVIX* and Apotex’s generic clopidogrel bisulfate product, which IMS had overstated for the months August 2006 through June 2007 due to market events surrounding the at-risk launch of generic clopidogrel bisulfate. Due to these unique circumstances, the high degree of volatility and the compressed timeframe of these events, IMS applied a custom approach to estimate PLAVIX* and generic clopidogrel bisulfate product and market volumes beginning in July 2007.

In October 2007, IMS issued a further Product News bulletin, announcing the discontinuation of the custom approach to estimate PLAVIX* and generic clopidogrel bisulfate product and market volumes in favor of its standard approach beginning October 2007.

The IMS overstatement of PLAVIX* prescription and unit volumes did not impact the Company’s financial results or its reported net sales for PLAVIX* for the quarters ended September 30, 2006, December 31, 2006, March 31, 2007 and June 30, 2007.

20

The following table sets forth the Company’s (i) previously reported estimated prescription change data and estimated therapeutic category share based on National Prescription Audit (NPA) data for the quarters ended September 30, 2006 and December 31, 2006; (ii) previously reported estimated prescription change data and estimated therapeutic category share based on NGPS version 2.0 data for the quarter ended March 31, 2007; and (iii) revised estimated prescription change data and estimated therapeutic category share based on revised NGPS version 2.0 data using the IMS custom approach.

	PLAVIX*				Clopidogrel Bisulfate (Branded and Generic)
	As Reported (NPA Data)		Revised (NGPS v2 Data)		As Reported (NPA Data)		Revised (NGPS v2 Data)
Change in U.S. Total Prescriptions
Three Months Ended March 31, 2007(a)	(28	)%	(36	)%	18	%	9	%
Three Months Ended December 31, 2006	(64	)	(70	)	14		11
Three Months Ended September 30, 2006	(32	)	(36	)	14		11
Twelve Months Ended December 31, 2006	(18	)	(21	)	14		12
Nine Months Ended September 30, 2006	(2	)	(4	)	N/A		N/A
Estimated TRx Therapeutic Category Share
Month Ended March 31, 2007(a)	65		62		N/A		N/A
Month Ended December 31, 2006	34		29		N/A		N/A
Month Ended September 30, 2006	23		19		N/A		N/A

(a) NGPS version 2.0 data

The estimated prescription change data and estimated therapeutic category share reported throughout this Form 10-Q only include information from the retail and mail order channels and do not reflect information from other channels, such as hospitals, institutions and long-term care, among others. The data provided by IMS are a product of IMS’ own record-keeping processes and are estimates based on IMS’ sampling procedures, subject to the inherent limitations of estimates based on sampling and a margin of error.

21

Estimated Inventory Months on Hand in the Distribution Channel

U.S. Pharmaceuticals

The following tables set forth for each of the Company’s top 15 pharmaceutical products (based on 2006 annual net sales) sold by the Company’s U.S. Pharmaceuticals business, the U.S. Pharmaceuticals net sales and the estimated number of months on hand of the applicable product in the U.S. wholesaler distribution channel for the quarters ended September 30, 2007 and 2006 and June 30, 2007 and 2006.

	September 30, 2007				September 30, 2006
Dollars in Millions	Net Sales			Months on Hand	Net Sales		Months on Hand
ABILIFY* (total revenue)	$	329		0.4	$	260	0.5
AVAPRO*/AVALIDE*		176		0.4		159	0.4
BARACLUDE		22		0.5		14	0.6
COUMADIN		40		0.6		45	0.7
ERBITUX*		183		0.3		173	0.5
GLUCOPHAGE* Franchise		17		0.6		20	0.7
KENALOG		20		0.6		19	0.8
ORENCIA		57		0.4		34	0.8
PARAPLATIN		(1	)	25.0		5	1.5
PLAVIX*		1,080		0.4		474	1.5
PRAVACHOL		17		0.7		73	1.0
REYATAZ		141		0.5		129	0.5
SPRYCEL		17		0.7		11	1.2
SUSTIVA Franchise (a) (total revenue)		151		0.6		128	0.5
ZERIT		13		0.7		19	0.7

	June 30, 2007			June 30, 2006
Dollars in Millions	Net Sales		Months on Hand	Net Sales		Months on Hand
ABILIFY* (total revenue)	$	322	0.4	$	267	0.5
AVAPRO*/AVALIDE*		170	0.4		167	0.5
BARACLUDE		20	0.7		9	0.7
COUMADIN		43	0.7		46	0.8
ERBITUX*		160	0.4		172	—
GLUCOPHAGE* Franchise		17	0.6		22	0.6
KENALOG		26	0.5		22	0.8
ORENCIA		53	0.5		18	0.3
PARAPLATIN		1	17.5		2	1.7
PLAVIX*		1,015	0.4		988	0.5
PRAVACHOL		47	0.5		128	1.0
REYATAZ		138	0.6		122	0.6
SPRYCEL		14	0.8		—	—
SUSTIVA Franchise (a) (total revenue)		147	0.7		115	0.5
ZERIT		15	0.7		18	0.7

(a) Beginning in the third quarter of 2006, the SUSTIVA Franchise includes sales of SUSTIVA, as well as revenue of bulk efavirenz included in the combination therapy, ATRIPLA*. The estimated months on hand of the product in the U.S. wholesale distribution channel only include branded SUSTIVA inventory.

In October 2004, the U.S. pediatric exclusivity period for PARAPLATIN expired. The resulting entry of multiple generic competitors for PARAPLATIN led to a significant decrease in demand for PARAPLATIN, which in turn led to the months on hand of the product in the U.S. wholesaler distribution channel exceeding one month on hand at September 30, 2007, June 30, 2007, September 30, 2006 and June 30, 2006. The estimated value of PARAPLATIN inventory in the U.S. wholesaler distribution channel over one month on hand was approximately $0.1 million at September 30, 2007, $0.3 million at June 30, 2007,

22

$0.6 million at September 30, 2006 and $1.4 million at June 30, 2006. The Company no longer produces PARAPLATIN for the U.S. market and will continue to monitor PARAPLATIN wholesaler inventory levels until they have been depleted.

At September 30, 2006, the estimated value of PLAVIX* inventory in the U.S. wholesaler distribution channel exceeded one month on hand by approximately $41.4 million due to the at-risk launch of generic clopidogrel bisulfate in August 2006. Because of the large quantities of generic clopidogrel bisulfate shipped into the distribution channels before the preliminary injunction was granted ordering the halt of sales of generic clopidogrel bisulfate in late August 2006, demand for branded PLAVIX* decreased precipitously.

SPRYCEL was launched in the U.S. in July 2006. Consistent with standard practice at the time of a new product launch, the Company’s U.S. wholesalers built inventories of the product to meet expected demand and at September 30, 2006, the estimated value of SPRYCEL inventory in the U.S. wholesaler distribution channel exceeded one month on hand by approximately $0.6 million. The Company worked down wholesaler inventory levels to one month on hand or less in the subsequent quarter.

For all products other than ERBITUX* and ORENCIA, the Company determines the above months on hand estimates by dividing the estimated amount of the product in the U.S. wholesaler distribution channel by the estimated amount of out-movement of the product from the U.S. wholesaler distribution channel over a period of 31 days, all calculated as described below. Factors that may influence the Company’s estimates include generic competition, seasonality of products, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, such estimates are calculated using third-party data, which represent their own record-keeping processes and as such, may also reflect estimates.

The Company maintains inventory management agreements (IMAs) with most of its U.S. Pharmaceuticals wholesalers, which account for nearly 100% of total gross sales of U.S. pharmaceutical products. Under the current terms of the IMAs, the Company’s three largest wholesaler customers provide the Company with weekly information with respect to inventory levels of product on hand and the amount of out-movement of products. These three wholesalers accounted for approximately 90% of total gross sales of U.S. Pharmaceuticals products in the third quarter of 2007. The inventory information received from these wholesalers excludes inventory held by intermediaries to whom they sell, such as retailers and hospitals, and excludes goods in transit to such wholesalers. The Company uses the information provided by these three wholesalers as of the Friday closest to quarter end to calculate the amount of inventory on hand for these wholesalers at the applicable quarter end. This amount is then increased by the Company’s estimate of goods in transit to these wholesalers based on the Company’s records of sales to these wholesalers, which have not been reflected in the weekly data provided by the wholesalers. Under the Company’s revenue recognition policy, sales are recorded when substantially all the risks and rewards of ownership are transferred, which in the U.S. Pharmaceuticals business is generally when product is shipped. In such cases, goods in transit to a wholesaler are owned by the applicable wholesaler and, accordingly, are reflected in the calculation of inventories in the wholesaler distribution channel. The Company determines the out-movement of a product from these wholesalers over a period of 31 days by using the most recent four weeks of out-movement of a product as provided by these wholesalers and extrapolating such amount to a 31 day basis. The Company estimates for each product, inventory levels on hand and out-movements for all its U.S. Pharmaceuticals business wholesaler customers, by adjusting the three largest wholesalers’ inventory levels and out-movements by a factor that approximates the other remaining wholesalers’ percentage share of total gross sales for such product in the U.S. In addition, the Company receives inventory information from these other wholesalers on a selective basis for certain key products.

The Company’s U.S. Pharmaceuticals business through the IMAs discussed above, has arrangements with substantially all of its direct wholesaler customers and requires those wholesalers to maintain inventory at levels that are no more than one month of their demand.

The Company distributes ORENCIA through distribution arrangements with multiple distributors. The above estimates of months on hand was calculated by dividing the inventories of ORENCIA held by these

23

distributors at the end of the quarter by the out-movement of the product over the last 31 day period, as reported by these distributors. The inventory on hand and out-movements reported by these distributors are a product of the distributors’ own record-keeping processes.

The Company sells ERBITUX* to intermediaries (such as wholesalers and specialty oncology distributors) and ships ERBITUX* directly to the end-users of the product who are the customers of those intermediaries. The Company also sells ERBITUX* to other distributors who then hold ERBITUX* inventory. The above estimate of months on hand was calculated by dividing the inventories of ERBITUX* held by the distributors for their own accounts as reported by the distributors as of the end of the quarter by the out-movements of the product reported by the distributors over the last 31 day period. The inventory levels reported by the distributors are a product of their record-keeping process.

24

International Pharmaceuticals, Nutritionals and Other Health Care

The following table sets forth for each of the Company’s key pharmaceutical products and other growth drivers sold by the Company’s International Pharmaceuticals reporting segment, including the top 15 pharmaceutical products sold in the Company’s major non-U.S. countries (based on 2006 net sales), and for each of the key products sold by the other reporting segments listed below, the percentage change in the Company’s estimated ultimate patient/consumer demand for the months of September 2007 and June 2007 compared to the same period in the prior year.

	% Change in Demand on a Constant U.S. Dollar Basis
	September 2007 vs. September 2006		June 2007 vs. June 2006
International Pharmaceuticals
ABILIFY* (total revenue)	35		45
AVAPRO*/AVALIDE*	10		0
BARACLUDE	*	*	*	*
BUFFERIN*	(64	)	(8	)
CAPOTEN	(16	)	(21	)
DAFALGAN	10		39
EFFERALGAN	17		29
MAXIPIME	(25	)	(18	)
MONOPRIL	(8	)	(25	)
ORENCIA	*	*	*	*
PERFALGAN	1		31
PLAVIX*	10		0
PRAVACHOL	(46	)	(64	)
REYATAZ	14		5
SPRYCEL	N/A		N/A
SUSTIVA Franchise (total revenue)	4		(1	)
TAXOL® (paclitaxel)	(25	)	(29	)
VIDEX/VIDEX EC	(20	)	(9	)
Nutritionals
ENFAMIL/ENFAGROW	15		4
NUTRAMIGEN	8		(3	)
Other Health Care
ConvaTec
Ostomy	(4	)	2
Wound Therapeutics	4		3
Medical Imaging
CARDIOLITE	(7	)	(2	)

** In excess of 200%

25

Estimated Inventory Months on Hand in the Distribution Channel

The following table sets forth for each of the Company’s key products sold by the reporting segments listed below, the net sales of the applicable product for each of the quarters ended September 30, 2007, June 30, 2007, September 30, 2006, and June 30, 2006 and the estimated number of months on hand of the applicable product in the direct customer distribution channel for the reporting segment as of the end of each of the four quarters. The estimates of months on hand for key products described below for the International Pharmaceuticals reporting segment are based on data collected for all of the Company’s significant business units outside of the U.S. Also described further below is information on non-key product(s) where the amount of inventory on hand at direct customers is more than approximately one month and the impact is not de minimis. For the other reporting segments, estimates are based on data collected for the U.S. and all significant business units outside of the U.S.

	September 30, 2007			June 30, 2007
Dollars in Millions	Net Sales		Months On Hand	Net Sales		Months On Hand
International Pharmaceuticals
ABILIFY* (total revenue)	$	91	0.6	$	90	0.6
AVAPRO*/AVALIDE*		133	0.5		127	0.5
BARACLUDE		50	0.6		39	0.7
BUFFERIN*		16	0.8		27	0.5
CAPOTEN		26	0.8		25	0.9
DAFALGAN		40	1.1		42	1.4
EFFERALGAN		71	0.9		69	1.4
MAXIPIME		30	0.7		39	0.8
MONOPRIL		43	1.2		42	1.2
ORENCIA		3	0.3		2	0.4
PERFALGAN		56	0.6		65	0.5
PLAVIX*		174	0.5		174	0.6
PRAVACHOL		69	0.6		85	0.6
REYATAZ		132	0.6		116	0.7
SPRYCEL		29	0.4		21	0.4
SUSTIVA Franchise (a) (total revenue)		86	0.5		86	0.5
TAXOL® (paclitaxel)		101	0.6		91	0.6
VIDEX/VIDEX EC		36	1.4		27	1.1
Nutritionals
ENFAMIL/ENFAGROW		355	0.9		337	0.9
NUTRAMIGEN		56	1.0		54	1.0
Other Health Care
ConvaTec
Ostomy		147	0.9		150	0.9
Wound Therapeutics		126	0.9		119	0.9
Medical Imaging
CARDIOLITE		99	0.8		106	0.7

(a) Beginning in the third quarter of 2006, the SUSTIVA Franchise includes sales of SUSTIVA, as well as revenue of bulk efavirenz included in the combination therapy, ATRIPLA*. The estimated months on hand of the product in the distribution channel only include branded SUSTIVA inventory.

26

	September 30, 2006			June 30, 2006
Dollars in Millions	Net Sales		Months on Hand	Net Sales		Months on Hand
International Pharmaceuticals
ABILIFY* (total revenue)	$	53	0.6	$	57	0.6
AVAPRO*/AVALIDE*		118	0.5		113	0.5
BARACLUDE		8	0.9		5	1.0
BUFFERIN*		28	0.5		31	0.5
CAPOTEN		28	0.8		31	0.9
DAFALGAN		35	1.1		37	1.1
EFFERALGAN		62	0.9		62	0.9
MAXIPIME		40	0.7		43	0.8
MONOPRIL		34	1.0		48	1.1
ORENCIA		—	—		—	—
PERFALGAN		48	0.6		51	0.6
PLAVIX*		156	0.6		157	0.5
PRAVACHOL		119	0.7		195	1.4
REYATAZ		104	1.1		114	0.7
SPRYCEL		—	—		—	—
SUSTIVA		73	0.5		78	0.5
TAXOL® (paclitaxel)		135	0.6		145	0.5
VIDEX/VIDEX EC		35	1.4		35	1.2
Nutritionals
ENFAMIL/ENFAGROW		315	0.8		312	0.9
NUTRAMIGEN		50	1.0		54	1.0
Other Health Care
ConvaTec
Ostomy		139	0.9		141	1.0
Wound Therapeutics		113	0.9		107	0.9
Medical Imaging
CARDIOLITE		97	0.8		105	0.8

The above months on hand information represents the Company’s estimates of aggregate product level inventory on hand at direct customers divided by the expected demand for the applicable product. Expected demand is the estimated ultimate patient/consumer demand calculated based on estimated end-user consumption or direct customer out-movement data over the most recent 31 day period or other reasonable period. Factors that may affect the Company’s estimates include generic competition, seasonality of products, direct customer purchases in light of price increases, new product or product presentation launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations.

The Company relies on a variety of methods to calculate months on hand for these reporting segments. Where available, the Company relies on information provided by third parties to determine estimates of aggregate product level inventory on hand at direct customers and expected demand. For the reporting segments listed above; however, the Company has limited information on direct customer product level inventory, end-user consumption and direct customer out-movement data. Further, the quality of third-party information, where available, varies widely. In some circumstances, such as the case with new products or seasonal products, such historical end-user consumption or out-movement information may not be available or applicable. In such cases, the Company uses estimated prospective demand. In cases where direct customer product level inventory, ultimate patient/consumer demand or out-movement data do not exist or are otherwise not available, the Company has developed a variety of other methodologies to calculate estimates of such data, including using such factors as historical sales made to direct customers and third-party market research data related to prescription trends and end-user demand.

27

As of September 30, 2007, June 30, 2007, September 30, 2006 and June 30, 2006, DAFALGAN, an analgesic product sold principally in Europe, had approximately 1.1 months, 1.4 months, 1.1 months, and 1.1 months of inventory on hand, respectively, at direct customers. The level of inventory on hand is due primarily to private pharmacists purchasing DAFALGAN approximately once every eight weeks and the seasonality of the product.

As of June 30, 2007, EFFERALGAN, an analgesic product sold principally in Europe, had approximately 1.4 months of inventory on hand, respectively, at direct customers. The level of inventory on hand is due primarily to private pharmacists purchasing EFFERALGAN approximately once every eight weeks and the seasonality of the product.

As of September 30, 2007, June 30, 2007, and June 30, 2006, MONOPRIL, a cardiovascular product, had approximately 1.2 months, 1.2 months and 1.1 months of inventory on hand, respectively, at direct customers. The levels of inventory on hand as of September 30, 2007 and June 30, 2007, is due primarily to initial stocking of a new, exclusive distributor in Poland and stocking in support of the launch of MONOPRIL in Poland in 2007. The level of inventory on hand as of June 30, 2006, was due primarily to supply of the product in support of its inclusion in a government program in Russia.

As of June 30, 2006, PRAVACHOL, a cardiovascular product, had approximately 1.4 months of inventory on hand, respectively, at direct customers. The increased level of inventory on hand was due primarily to an increase in orders from a significant direct customer in France.

As of September 30, 2006, REYATAZ, an antiviral product, had approximately 1.1 months on hand at direct customers. The increased level of inventory on hand is due primarily to government purchasing patterns in Brazil.

As of September 30, 2007, June 30, 2007, September 30, 2006 and June 30, 2006, VIDEX/VIDEX EC, an antiviral product, had approximately 1.4 months, 1.1 months, 1.4 months, and 1.2 months of inventory on hand at direct customers. The increased level of inventory on hand is due primarily to government purchasing patterns in Brazil. The Company is contractually obligated to provide VIDEX/VIDEX EC to the Brazilian government upon placement of an order for product by the government. Under the terms of the contract, the Company has no control over the inventory levels relating to such orders.

The Company continuously seeks to improve the quality of its estimates of months on hand of inventories held by its direct customers including thorough review of its methodologies and processes for calculation of these estimates and review and analysis of its own and third parties’ data used in such calculations. The Company expects that it will continue to review and refine its methodologies and processes for calculation of these estimates and will continue to review and analyze its own and third parties’ data in such calculations.

28